Drug intelligence / Profile preview

SHR-1139

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Administration: Subcutaneous, Intravenous

Overview

SHR-1139 is an investigational drug developed by Guangdong Hengrui Pharmaceutical for the treatment of moderate to severe plaque psoriasis. It is currently in Phase 2 clinical trials in China, with studies evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics following subcutaneous or intravenous administration. The precise mechanism of action for SHR-1139 has not been disclosed publicly.

Beyond the preview

Go deeper on SHR-1139.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-1139.

Explore the full profile